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Abstract
Mucopolysaccharidoses (MPS) are a subgroup of 11 monogenic lysosomal storage disorders due to the deficit of activity
of the lysosomal hydrolases deputed to the degradation of mucopolysaccharides. Although individually rare, all together
they account for at least 1:25,000 live births. In this study, we present the genetic analysis of a population of 71 MPS
patients enrolled in a multicenter Italian study. We re-annotated all variants, according to the latest recommendations, and
re-classified them as suggested by the American College of Medical Genetics and Genomics. Variant distribution per type
was mainly represented by missense mutations. Overall, 10 patients had received no molecular diagnosis, although 6 of
them had undergone either HSCT or ERT, based on clinical and enzymatic evaluations. Moreover, nine novel variants are
reported.
Conclusions: Our analysis underlines the need to complete the molecular diagnosis in patients previously diagnosed only on a
biochemical basis, suggests a periodical re-annotation of the variants and solicits their deposition in public databases freely
available to clinicians and researchers. We strongly recommend a molecular diagnosis based on the analysis of the “trio” instead
of the sole proband. These recommendations will help to obtain a complete and correct diagnosis of mucopolysaccharidosis,
rendering also possible genetic counseling.
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What is known
• MPS are a group of 11 metabolic genetic disorders due to deficits of enzymes involved in the mucopolysaccharides degradation.
• Molecular analysis is commonly performed to confirm enzymatic assays.
What is new
• Eighty-six percent of the 71 patients we collected received a molecular diagnosis; among them, 9 novel variants were reported.
• We stress the importance of molecular diagnosis in biochemically diagnosed patients, encourage a periodical re-an notation of variants according to
the recent nomenclature and their publication in open datbases.
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Abbreviations
ACMG American College of Medical Genetics
and Genomics
CNV Copy number variations
ERT Enzyme replacement therapy
GAG Glycosaminoglycans
HGVS Human Genome Variation Society
HSCT Hematopoietic stem cells transplantation
MPS Mucopolysaccharidosis(es)
WES Whole exome sequencing
WGS Whole genome sequencing
Introduction
Mucopolysaccharidoses (MPS) are very rare, monogenic,
metabolic disorders due to the deficit of the lysosomal en-
zymes normally degrading mucopolysaccharides or glycos-
aminoglycans (GAG), this causing their pathological accumu-
lation in most tissues and organs. GAG accumulation progres-
sively leads to cell dysfunction and death causing impairment
of most organ/systems, including the brain in about two-thirds
of the cases.
Incidence of MPS varies for each disorder and in different
populations and ethnic groups, with overall prevalence going
from 1.2 up to 16.9 over 100,000 live births recorded in the
USA and Saudi Arabia, respectively [32].
MPS diagnosis normally proceeds from clinical suspicion,
going through biochemical analysis, including urinary GAG
and enzymatic assays, and is confirmed by molecular diagno-
sis [21].
Beyond symptomatic therapies, in the last 10–15 years
treatment of these disorders has been mainly accomplished
by enzyme supplementation, the so-called enzyme replace-
ment therapy (ERT), available for MPS I, MPS II, MPS
IVA, and MPS VI. Also, hematopoietic stem cell transplanta-
tion (HSCT) has been successfully applied almost exclusively
to MPS I, while still debated for other MPS [9]. In addition to
commonly requiring weekly hospitalization, ERT is an expen-
sive procedure implicating important investments from the
National Health Care Systems. Therefore, ethical and
economic reasons impose its application to patients with a
definite diagnosis.
In this study, we collected and evaluated the molecular
diagnosis of a group of MPS patients enrolled in a multicenter
Italian study, underlining its importance, together with enzy-
matic assays, to confirm the MPS clinical suspect and to reach
a correct diagnosis. Importantly, a definite molecular diagno-
sis represents an essential tool for effective genetic counseling.
Materials and methods
Seventy-one subjects affected by MPS were enrolled in a
multicenter Italian study, financed by the Italian Ministry
of Education, University and Research (MIUR), planning,
among others, the collection of clinical, biochemical, and
molecular data during a follow-up evaluation. All proce-
dures performed were in accordance with the ethical stan-
dards of the institutional research committee and with the
1964 Helsinki declaration and its later amendments.
Informed consent was obtained from all individual partic-
ipants included in the study. Here, we report data related to
genetic diagnoses, which were performed in different lab-
oratories applying, in most cases, standard molecular
methods (PCR amplification and Sanger sequencing); in
few specific cases, second- or third-level analyses were
conducted aiming to detect gross deletions, rearrange-
ments, CNVs, or deep intronic variants. Genetic data was
extrapolated from a web-based platform shared among the
different units. For the patients with no molecular diagno-
sis available, molecular genetic analysis was not feasible at
the time of enrollment in the present study, as patients’
DNA samples were not available. Variants reported in the
original diagnostic reports were checked using Name
Checker (https://www.mutalyzer.nl/name-checker) and,
when necessary, were re-annotated on the basis of the most
recent HGVS nomenclature (version 15.11; http://www.
hgvs.org/nutnomen/). In addition, the novel missense
variants were in silico tested for pathogenicity with four
different prediction tools: DANN [47], MutationTaster
[52], GERP [16], SIFT [55]; moreover, a structural
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evaluation of the impact of the amino acid substitution on
the enzyme structure was performed through the tool
HOPE [65]. Finally, all variants were further analyzed,
(re-)classified according to the criteria suggested by the
American College of Medical Genetics and Genomics
(ACMG) [50] and submitted to ClinVar database (https://
www.ncbi.nlm.nih.gov/clinvar/) where they will be
publicly available.
Results and discussion
In the population examined, 16 patients were affected by
MPS II (22.5%), 13 by MPS IIIA (18.3%), 12 by MPS IVA
(16.9%), 9 by MPS I (12.7%), 9 by MPS IIIB (12.7%), 7
by MPS VI (9.9%), 2 by MPS IIIC, 2 by MPS IVB, and 1
patient was affected by MPS IIID (Table 1). Molecular
diagnosis had been performed for 61 subjects out of 71
enrolled in the study (85.9%). Age at diagnosis varied for
the different disorders and severity. Generally, severe
forms were diagnosed earlier, likely due to the early ap-
pearance of first clinical signs and symptoms. This is evi-
dent when different forms are described within the same
disease, as in MPS I and MPS II. A significant difference
between severe and attenuated forms was registered in our
population for MPS I, with an average of 1.1 and 6.3 years
at diagnosis respectively. This was also registered for MPS
II, with an average of 2.9 and 6.6 years at diagnosis respec-
tively (this last value was calculated excluding patient P14,
a subject presenting a mild phenotype, who was diagnosed
at 44.3 years of age).
As for MPS IIIA and MPS IIIB, in our population diagno-
sis was reached on average around 5 years of age, except in
one case of MPS IIIB, reported with an attenuated phenotype,
and diagnosed at 18 years of age [23]. Most, if not all, MPS
IVA cases were reported as severe and diagnosis was achieved
on average at 3.2 years of age. The only 2 cases registered for
MPS IVB are both reported with a mild phenotype and were
diagnosed around 10 years of age. MPS VI, although com-
monly not affecting neurological functions, usually presents a
severe skeletal phenotype, thus early diagnosis can be obtain-
ed. In our population, mean age at diagnosis for MPS VI was
1.8 years.
Distribution of diagnosed patients in the different MPS
types is shown in Fig. 1. A missing molecular diagnosis
was registered in 4/9 MPS I patients, 2/16 patients affected
by MPS II, 1/13 MPS IIIA patients, and 3/9 MPS IIIB
patients. Thus, for MPS I and MPS II patients, for whom
either HSCT or ERT have been available for several years,
a total of 6 out of 25 patients did not receive a molecular
definition. Three of them underwent HSCT and 3
underwent ERT, based on clinical and biochemical evalu-
ations. For 4 of them, molecular analysis of the genes was
not feasible at the time of diagnosis. For all of them, it was
never completed afterward.
As for the MPS IIIA and B patients, 4 of which remained
molecularly undiagnosed, we suggest this may be due to the
delay with which MPS III patients are sometimes clinically
recognized and also to the lack of treatments for all MPSIII,
which may cause a limited clinical follow-up with time.
Overall, of the 10 patients with no molecular diagnosis, 7
had been clinically diagnosed 20 or more years ago, while
most of the patients (70%) with molecular diagnosis came to
the clinical observation more recently in the last 15 years.
Thus, we could argue that in the past, molecular diagnosis
likely did not receive significant attention in the completion
of the patient diagnosis, given also the fact that some MPS
genes were identified in the early 2000s. Moreover, an evalu-
ation of the timing elapsed between clinical/enzymatic diag-
nosis and molecular diagnosis showed in general, for all MPS
taken together, a delay of about 4.6 years of the molecular
diagnosis with respect to the clinical/enzymatic diagnosis,
with a range from 0 up to 22 years.
A summary of all identified genotypes is reported in
Table 1. Since for some patients, variants had been identified
several years ago, we checked all of them and when necessary
we re-annotated them according to the most recent HGVS
nomenclature. On the whole, we report 87 variants, of which
67 are unique. Nine of the reported variants had never been
described in the literature before.
Analysis of the genetic alterations identified in the exam-
ined population showed that, as expected, most of the variants
were missense (about 70%), followed by small deletions (9%),
large deletions/rearrangements (7.5%), splicing (7.5%), non-
sense (4.5%) and sense variants (1.5%) (Table 2). In the con-
text of MPS, we need to consider that while small variants may
be identified in all disorders, other variants, as complex rear-
rangements, may be more easily encountered in subjects af-
fected by MPS II due to homologous recombinational events
between the iduronate 2-sulfatase gene (IDS) and its
pseudogene (IDS2) [48].
Finally, Fig. 2 shows, for each MPS, the number of
patients carrying the variant in hemizygosis or homozygo-
sis. Homozygous mutations have been confirmed in par-
ents for 15 out of 23 homozygous patients, thus excluding
the presence of deletions on a single allele. In one case,
P27, only the mother was analyzed, while for patient P32,
only the sister was analyzed. For patient P69, carrying a
homozygous deletion of exon 5 of ARSB gene, the homo-
zygosis status was unequivocally confirmed by mRNA
analysis. For the remaining 5 patients, analysis of any par-
ents or relatives was not available. However, for 4 of them
parents were consanguineous, rendering unlikely the
chances of “apparent homozygosity.”
Homozygous patients provide a valuable tool to evalu-
ate the in vivo effect of each specific variant, helping to
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possibly define genotype/phenotype correlations. In this
respect, we underline as such evaluations may only be pos-
sible based on a strict collaboration between clinics, defin-
ing the patient phenotype based on shared severity criteria,
and laboratory, carrying out the molecular analysis. In ad-
dition, information on parents’ ethnicity and consanguinity
provided to the laboratory would be very important for the
interpretation of the obtained molecular results and for ge-
netic counseling.
Apart from MPS II which, being an X-linked disorder, is
always caused by a single pathogenic variant (hemizygous
condition), 6/12 of the MPS IIIA as well as 6/12 of the
MPS IVA patients presented a condition of homozygosis.
Also, 2 MPS IIIB, 2 MPS IIIC, and 1 MPS IIID patients
showed a condition of homozygosis. Interestingly, 6 out of
the 7 MPS VI patients presented a condition of homozy-
gosity for different pathogenic variants; this reflects a gen-
eral condition for this disorder in which a wide analysis of
the literature has shown that more than 55% of the patients
present genomic homozygosity for different pathogenic
variants of the ARSB gene [58].
Eleven of the 23 homozygous patients had consanguin-
eous parents, this explaining homozygosity, in these cases
likely independent from the geographical distribution of
the variants. It is known that gross deletions or gene rear-
rangements are commonly associated with severe clinical
phenotypes. In our study, this was confirmed in 3 MPS II
severe patients, whose causative mutations were represent-
ed by the deletion of several exons of the IDS gene (P19 in
Table 1), deletion of the whole IDS gene (P25) and an
event of homologous recombination between IDS gene
and pseudogene (P23). This was also seen in MPS VI,
where the deletion of exon 5 of the ARSB gene was asso-
ciated with a severe phenotype (P69 and P70, Table 1).
Table 3 summarizes the phenotypes found in this study in
homozygous patients carrying point mutations and those
described in the literature with the same variants.
As for the other 11 IDS variants identified in this study,
mainly represented by missense mutations or small dele-
tions, most of which is previously described, they were in
the literature variably associated with either severe or at-
tenuated or mild phenotypes (Table 3). Five of them are
reported as associated with the same phenotype reported
previously in other patients: 2 of them confirming a mild
phenotype (P12 and P21 in Table 3) and 3 of them
confirming a severe phenotype (P13, P20, and P22 in
Table 3). However, the small number of patients analyzed
for each variant does not allow drawing conclusions on
these genotype-phenotype correlations.
With regards to homozygous patients identified in all
MPS, but in MPS I and MPS IVB, a genotype-phenotype
correlation analysis was conducted in 6 MPS IIIA patients,
3 of which confirming a previously described phenotype
(P26, P34, and P35 in Table 3). For the other 3 homozy-
gotes, no confirmation of previously described phenotypes
was possible, thus not allowing to hypothesize any
genotype-phenotype correlation. Concerning MPS IVA, 2
homozygous patients out of 6 confirmed previously de-
scribed severe phenotypes (P56 and P60). Finally, as for
MPS VI, none of the homozygotes’ phenotypes unequivo-
cally correlated with previously described patients
(Table 3), therefore we could not confirm any genotype-
phenotype correlations. Of the 2 patients showing a mild
phenotype, one was carrying in homozygosis the variant
c.245T>C (P71 in Table 1), previously undescribed. Other
genotype-phenotype correlations for this gene could be in-
ferred indirectly; as for the splicing variant c.1213+6T>C,
this was identified in homozygosis in a severe patient and
in heterozygosis in a mild patient, compound heterozygote
for the variant c.725A>C. This last variant, still presenting
“not enough evidence” of pathogenicity according to
ACMG classification, could confer the mild phenotype.
In addition, the novel missense variants [IDS: c.811A>T;
IDS: c.1563A>T; IDS: c.542A>G, SGSH: c.542A>G,
Fig. 1 Number of patients with
and without a molecular diagnosis
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NAGLU: c.1144G>T, and ARSB: c.245T>C] were evaluated
for pathogenicity with four different prediction tools
(DANN, Mutation Taster, GERP and SIFT) which all con-
firmed the potential pathogenicity of the tested variants.
This was also confirmed by the application of the tool
HOPE that predicted potential remarkable structural
changes in the enzyme structures which could affect the
catalytic activity of the examined proteins. Results of the
mentioned in silico evaluations are reported in the Online
Resource.
Finally, all variants were re-evaluated according to the re-
cent classification of ACMG (Table 2). The results of this
evaluation evidenced that more than half of the variants (al-
most 56%) fell into the “Likely pathogenic” class, 31% into
the “Not enough evidence” class, and the remaining resulted
“Pathogenic” (13%).
Conclusions
The present study underlines the need to complete the di-
agnostic workup of MPS patients previously diagnosed on
a biochemical basis, through the identification and, possi-
bly, the validation of the related gene variants. Molecular
diagnosis is essential to confirm an enzyme deficit and
provides diagnostic certainty to disorders for which the
application of available treatments requires hospitalization
and is extremely expensive. Moreover, we strongly recom-
mend a molecular diagnosis based on the analysis of the
“trio” instead of the sole proband, thus allowing the correct
definition of the family inheritance and the identification of
the de novo variants, which require different counseling.
Finally, we suggest a periodical re-annotation of the vari-
ants according to the most recent version of HGVS nomen-
clature and solicit laboratories to perform their deposition
in public databases (as LOVD, ClinVar, etc.), freely avail-
able to all clinicians and researchers. These recommenda-
tions will help obtain a complete and correct diagnosis of
mucopolysaccharidosis, rendering also possible genetic
counseling.
In these last years, molecular diagnosis of MPS, and in
general of monogenic-inherited disorders, has taken ad-
vantage of new analytical approaches which have widen
the possibility of investigation and have shortened the
timing of diagnosis. This includes next-generation se-
quencing, applied to targeted genes (panels) or, more wide-
ly, to exome (whole exome sequencing, WES) or genome
analyses (whole genome sequencing, WGS). Moreover,
validation of the new genomic variants can now partly take
advantage of the availability of several public databases
collecting exomic or genomic data from large scale se-
quencing projects (ExAC, gnomAD, etc.).Ta
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Fig. 2 Number of heterozygous
and homozygous/hemizygous
patients in each MPS
Table 3 List of point mutations found in hemizygosis and homozygosis and the corresponding phenotypes found in our cohort of patients and in the
literature
Gene Nucleotide change Predicted amino
acid change
Phenotypes of homozygous/hemizygous
patients described in our cohort
Phenotypes of homozygous/hemizygous
patients described in literature
IDS c.187A>G p.(Asn63Asp) Mild (P12) Mild [26]; intermediate [30]; attenuated [62];
attenuated [18]
c.359C>G p.(Pro120Arg) Severe (P13) Severe to intermediate [27]; severe [33]
c.592G>A p.(Asp198Asn) Severe (P22) Severe [1]
c.708G>A p.(Lys236Lys) Mild (P21) Intermediate [49]
c.1264 T>C p.(Cys422Arg) Mild (P10) severe [38]
c.1400C>T p.(Pro467Leu) Severe (P24) Phenotype not reported [22]
c.1403G>A p.(Arg468Gln) Severe (P20) Severe [71]; severe [57]; severe [67];
four severe patients [63]; severe [34];
three severe patients [35]; severe [31];
severe [25]; severe [18]
c.1478G>C p.(Arg493Pro) Severe (P17) Phenotype not reported [46]
SGSH c.197C>G p.(Ser66Trp) Severe (P27) Two severe, three intermediate, one
unknown [17]
c.220C>T p.(Arg74Cys) Severe (P26) Severe [41]; unknown [72]
c.544C>T p.(Arg182Cys) Severe (P33) No homozygotes described in literature
c.617G>C p.(Arg206Pro) Mild (P32) The same patient reported in the present study
was des cribed in [23]
c.1080del p.(Val361Serfs*52) Severe (P34, P35) Severe [69]; three severe patients [37];
two severe patients [3]; severe [19];
severe [64]
NAGLU c.274T>C p.(Tyr92His) Severe (P47) No homozygotes described in literature
c.874G>A p.(Gly292Arg) Severe (P46) No homozygotes described in literature
HGSNAT c.852-1G>A – Mild to severe (P48, P49) The same patients reported in the present study
were described in [20]
GNS c.814C>T p.(Gln272*) Severe (P50) The same patient reported in the present study
was described in [6]
GALNS c.29G>A p.(Trp10*) Severe (P56) Unknown [12]; severe [60]
c.1519T>C p.(Cys507Arg) Severe (P60) Severe [14]
c.1520G>T p.(Cys507Phe) Severe (P53, P54) No homozygotes described in literature
ARSB c.323G>T p.(Gly108Val) Severe (P65) No homozygotes described in literature
c.944G>A p.(Arg315Gln) Severe (P67) Intermediate [68]; severe [45]; five patients
with not reported phenotype [29]
c.1213+6T>C – Severe (P68) The same patient reported in the present study
was described in [42]
Eur J Pediatr
These tools, used with the appropriate critical evaluation,
may now allow more rapid and correct identification and val-
idation of the genomic variants associated with a specific clin-
ical phenotype.
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